fda warning letters compounded semaglutide tirzepatide 2025 issued 25 to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of Why the FDA Issued 30

The growing interest in pediatric obesity treatment, for which semaglutide has already received regulatory approvals in the adolescent population (12-17 years) in the United States and European Union, creates an additional patient population segment with significant long-term API volume implications as lifetime therapy becomes the standard of care for early-onset metabolic disease

However, it is currently investigational and not yet approved beyond trials

Your order ships discreetly from within Canada in 24 business days

One of the possible downsides of eating less while on Semaglutide is losing muscle as well as fat